Log on / register
Feedback | Support | My details
ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially.
Vantaggiato C, Formentini I, Bondanza A, Bonini C, Naldini L, Brambilla R
J Biol 2006, 5:14
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]


printer friendly 
to  [Help]

PubMed Central articles that cite the above article:

1.
Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis.
Shaw AT, Meissner A, Dowdle JA, Crowley D, Magendantz M, Ouyang C, Parisi T, Rajagopal J, Blank LJ, Bronson RT, Stone JR, Tuveson DA, Jaenisch R, Jacks T
Genes Dev 2007 Mar 15, 21:694-707
 [PubMed Central] [PubMed] [Related articles]
2.
Single and combined silencing of ERK1 and ERK2 reveals their positive contribution to growth signaling depending on their expression levels.
Lefloch R, Pouysségur J, Lenormand P
Mol Cell Biol 2008 Jan, 28:511-27
 [PubMed Central] [PubMed] [Related articles]
3.
Targeting the MEK1 cascade in lung epithelium inhibits proliferation and fibrogenesis by asbestos.
Manning CB, Sabo-Attwood T, Robledo RF, Macpherson MB, Rincón M, Vacek P, Hemenway D, Taatjes DJ, Lee PJ, Mossman BT
Am J Respir Cell Mol Biol 2008 May, 38:618-26
 [PubMed Central] [PubMed] [Related articles]
4.
ERK1 and ERK2 MAPK are key regulators of distinct gene sets in zebrafish embryogenesis.
Krens SF, Corredor-Adámez M, He S, Snaar-Jagalska BE, Spaink HP
BMC Genomics 2008, 9:196
 [PubMed Central] [PubMed] [Related articles]
5.
The ERK mitogen-activated protein kinase pathway contributes to Ebola virus glycoprotein-induced cytotoxicity.
Zampieri CA, Fortin JF, Nolan GP, Nabel GJ
J Virol 2007 Feb, 81:1230-40
 [PubMed Central] [PubMed] [Related articles]
6.
ERK signaling regulates tumor promoter induced c-Jun recruitment at the Fra-1 promoter.
Adiseshaiah P, Li J, Vaz M, Kalvakolanu DV, Reddy SP
Biochem Biophys Res Commun 2008 Jun 27, 371:304-8
 [PubMed Central] [PubMed] [Related articles]
7.
Reciprocal regulation of extracellular signal regulated kinase 1/2 and mitogen activated protein kinase phosphatase-3.
Zeliadt NA, Mauro LJ, Wattenberg EV
Toxicol Appl Pharmacol 2008 Nov 1, 232:408-17
 [PubMed Central] [PubMed] [Related articles]
8.
The N-terminal domain of ERK1 accounts for the functional differences with ERK2.
Marchi M, D'Antoni A, Formentini I, Parra R, Brambilla R, Ratto GM, Costa M
PLoS One 2008, 3:e3873
 [PubMed Central] [PubMed] [Related articles]
9.
ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.
Aceves-Luquero CI, Agarwal A, Callejas-Valera JL, Arias-González L, Esparís-Ogando A, del Peso Ovalle L, Bellón-Echeverria I, de la Cruz-Morcillo MA, Galán Moya EM, Moreno Gimeno I, Gómez JC, Deininger MW, Pandiella A, Sánchez Prieto R
PLoS One 2009, 4:e6124
 [PubMed Central] [PubMed] [Related articles]
10.
Erk1/2 MAP kinases are required for epidermal G2/M progression.
Dumesic PA, Scholl FA, Barragan DI, Khavari PA
J Cell Biol 2009 May 4, 185:409-22
 [PubMed Central] [PubMed] [Related articles]

This article is also cited by 3 articles in BioMed Central

printer friendly 
to  [Help]
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.